Categories
BT Catalyst

Wyeth-Lederle Dedicates New Facility

Wyeth-Lederle Dedicates New Facility Wyeth-Lederle Vaccines and Pediatrics celebrated the completed 24,000-square-foot expansion of its production facility in Sanford, N.C. at a ceremony in April. Gov. Jim Hunt accepted a $10,000 check from John R. Stafford, the chairman, president and CEO of Wyeth-Lederle’s parent company, American Home Products Corp., in support of the North Carolina […]

Categories
BT Catalyst

Link Closes On Round Of Funding

Link Closes On Round Of Funding Research Triangle Park-based Link Technology Inc. has closed on a $750,000 round of financing, including a $500,000 investment by Access Investment Partners of Westport, Conn. To date, the development-stage company has raised $2 million from the sale of convertible preferred stock to accredited individual investors, in addition to the […]

Categories
BT Catalyst

LabCorp to expand presence in Northern California

LabCorp to expand presence in Northern California LabCorp (Nyse: LH) of Burlington has agreed to pay $4.5 million in cash to purchase certain assets in Northern California from Quest Diagnostics Inc. (Nyse: DGX) following that company’s acquisition of Unilab Corp.of Tarzana, Calif. LabCorp’s acquisition will include four contracts with independent physician associations and leases for […]

Categories
BT Catalyst

Medical manufacturer will expand W-S facility, add jobs

Medical manufacturer will expand W-S facility, add jobs Gov. Mike Easley announced recently that Charter Medical Ltd., a medical manufacturing company, will expand its Winston-Salem plant, creating 50 jobs and a $600,000 investment. Charter is consolidating the operations of its Lakewood, N.J., facility with its existing operations in Forsyth County. “North Carolina’s competitive edge is […]

Categories
BT Catalyst

TransTech closes on $34.5m

TransTech closes on $34.5m TransTech Pharma Inc. of High Point recently closed on two rounds of preferred stock agreements totaling $24.5 million. The company will use a portion of the proceeds to advance two small-molecule programs toward clinical trials and three others into pre-clinical testing. The company’s Translational Technology TM, an automated and integrated drug […]

Categories
BT Catalyst

Biotech People

Biotech People * Jan P. Turek has been named the new president and CEO of Biolex Inc. of Pittsboro. Turek was previously senior vice president and general manager for the pharmaceutical division of Bayer Corp.’s biological products business unit in Raleigh. He will apply the global biopharmaceutical experience he gained at Bayer to help take […]

Categories
BT Catalyst

Duke University Medical Center

Duke University Medical Center Dr. Pascal J. Goldschmidt, chief of the division of cardiology at Duke University Medical Center in Durham, has been selected to chair the department of medicine at Duke. Goldschmidt is the Edward S. Orgain Professor of Cardiology and director of the Center for Cardiovascular Genetics. He succeeds Dr. Barton Haynes, who […]

Categories
BT Catalyst

Delta Pharm. Enters Analgesic Market With A Bang

Delta Pharm. Enters Analgesic Market With A Bang In 1996, Delta Pharmaceuticals Inc. was a startup tucked away in a Chapel Hill home and 2,000 square feet of laboratory space in the depths of the Research Triangle Institute campus. Just three years later, Delta is ready to break out of a mild existence since attaining […]

Categories
BT Catalyst

PharmNetics raises $9.58m

PharmNetics raises $9.58m PharmaNetics Inc. (Nasdaq/NM: PHAR) of Raleigh has raised $9.58 million through a private placement of preferred stock. The proceeds of the offering will be used to build sales momentum for the company’s ENOX test, a rapid, point-of-care test to detect the anticoagulant effects of enoxaparin sodium. The financing was led by Camden […]

Categories
BT Catalyst

Trimeris, Roche Broaden Scope Of Hiv Partnership

Trimeris, Roche Broaden Scope Of Hiv Partnership Trimeris Inc. of Durham and Hoffmann-La Roche Inc. of Nutley, N.J., have expanded a worldwide partnership agreement to discover, develop and commercialize novel generations of HIV fusion-inhibitor peptides. First signed in 1999, the agreement between the two companies is focused on T-20 and T-1249, two investigational HIV fusion […]